Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial

European Journal of Cancer

Volumn 48, Issue 3, 2012, Pages 311-323

  Cella, D ^a   Pickard, A S ^b   Duh, M S ^c   Guerin, A ^d   Mishagina, N ^d   Antras L ^c   Neary, M P ^e   McCann, L ^e   Hodge, R ^f   Sternberg, C N ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ANALYSIS GROUP   (United States)

^d Groupe d'Analyse Ltee   (Canada)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Health related quality of life; Metastatic RCC; Pazopanib; Renal cell carcinoma

Indexed keywords

PAZOPANIB; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DETERIORATION; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER SCALE; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE CORE 30; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIMIDINES; QUALITY OF LIFE; SULFONAMIDES;

EID: 84856213031     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.05.017     Document Type: Article

References (15)

1. D. Cella, J.Z. Li, and J.C. Cappelleri Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial J Clin Oncol 26 22 2008 3763 3769
2. J.S. Lam, A. Breda, A.S. Belldegrun, and R.A. Figlin Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma J Clin Oncol 24 35 2006 5565 5575 (Pubitemid 46631337)
3. Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 2009. doi: 10.1016/j.ctrv.2009.07.003.
4. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced and/or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 6 2010 1061 1068
5. R. Bukowski, D. Cella, K. Gondek, and B. Escudier Effects of sorafenib on symptoms and quality of life (QoL): results from a large randomized placebo-controlled study in renal cancer Am J Clin Oncol 30 2007 220 227 (Pubitemid 46884139)
6. F.F. Kabbinavar, J.F. Wallace, and E. Homgren Health-related quality of life impact of bevacizumab when combined with irnotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer The Oncologist 13 2008 1021 1029
7. P. Dolan Modeling valuations for EuroQol health states Med Care 35 11 1997 1095 1108 (Pubitemid 127453463)
8. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144 (Pubitemid 28041591)
9. A.S. Pickard, M.P. Neary, and D. Cella Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer Health Qual Life Outcomes 5 2007 70
10. Awad L, Emmanuel Z, Mesbah M. Applying survival data methodology to analyse longitudinal quality of life data. In: Mesbah Mounir, Cole Bernard F, Ting Lee Mei-Ling, editors. Statistical methods for quality of life studies: design, measurement, and analysis. Kluwer Academic Publishers; 2002. p. 231-43.
11. FDA's guidance for industry - patient-reported outcome measures: use in medical product development to support labeling claims. Available from: < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf > [accessed 01.04.11].
12. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 2007 115 124 (Pubitemid 46089672)
13. Szczylik C, Cella D, Eisen T, et al. Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs. interferon-α (IFN). J Clin Oncol 2008;26(20 Suppl.) [abstr 9603].
14. Parasuraman P, Hudes G, Levy DE, et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN+TEMSR. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2007;(20 Suppl.) [25(18S): 5049].
15. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma; a double-blind, randomised, placebo controlled phase III trial Lancet 372 2008 449 456